Figure 5.
Figure 5. Representative box plots showing distribution of IC50imatinib in those patients with a low Sokal score, grouped as achievement or nonachievement of the noted milestones. Values within the 25th to 75th percentile are enclosed within the shaded area. Median is as indicated, 5th and 95th percentiles are shown by error bars, and outliers are delineated as discrete dots. (A) Distribution of IC50imatinib in those patients who achieved a 0- to 2-log reduction in BCR-ABL by 3 months versus those who achieved a greater than 2-log reduction by 3 months. (B) Distribution of IC50imatinib in those patients who achieved a 0- to 3-log reduction in BCR-ABL by 12 months versus those who achieved a greater than 3-log reduction by 12 months.

Representative box plots showing distribution of IC50imatinib in those patients with a low Sokal score, grouped as achievement or nonachievement of the noted milestones. Values within the 25th to 75th percentile are enclosed within the shaded area. Median is as indicated, 5th and 95th percentiles are shown by error bars, and outliers are delineated as discrete dots. (A) Distribution of IC50imatinib in those patients who achieved a 0- to 2-log reduction in BCR-ABL by 3 months versus those who achieved a greater than 2-log reduction by 3 months. (B) Distribution of IC50imatinib in those patients who achieved a 0- to 3-log reduction in BCR-ABL by 12 months versus those who achieved a greater than 3-log reduction by 12 months.

Close Modal

or Create an Account

Close Modal
Close Modal